|
1
|
Sun HC and Tang ZY: Angiogenesis in
hepatocellular carcinoma: The retrospectives and perspectives. J
Cancer Res Clin Oncol. 130:307–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Folkman J: Angiogenesis: An organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van de Veire S, Stalmans I, Heindryckx F,
Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx
B, Vinckier S, et al: Further pharmacological and genetic evidence
for the efficacy of PlGF inhibition in cancer and eye disease.
Cell. 141:178–190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weis SM and Cheresh DA: Tumor
angiogenesis: Molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sharma PS, Sharma R and Tyagi T:
VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: Present
and future. Curr Cancer Drug Targets. 11:624–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ribatti D, Ranieri G, Basile A, Azzariti
A, Paradiso A and Vacca A: Tumor endothelial markers as a target in
cancer. Expert Opin Ther Targets. 16:1215–1225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Avramis IA, Kwock R and Avramis VI:
Taxotere and vincristine inhibit the secretion of the angiogenesis
inducing vascular endothelial growth factor (VEGF) by wild-type and
drug-resistant human leukemia T-cell lines. Anticancer Res.
21:2281–2286. 2001.PubMed/NCBI
|
|
9
|
Lee JH, Choi S, Lee Y, Lee HJ, Kim KH, Ahn
KS, Bae H, Lee HJ, Lee EO, Ahn KS, et al: Herbal compound
farnesiferol C exerts antiangiogenic and antitumor activity and
targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1)
signaling cascades. Mol Cancer Ther. 9:389–399. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yue GG, Fan JT, Lee JK, Zeng GZ, Ho TW,
Fung KP, Leung PC, Tan NH and Lau CB: Cyclopeptide RA-V inhibits
angiogenesis by down-regulating ERK1/2 phosphorylation in HUVEC and
HMEC-1 endothelial cells. Br J Pharmacol. 164:1883–1898. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li R, Zhao H and Lin Y: Anti-tumor effect
and protective effect on chemotherapeutic damage of water soluble
extracts from Hedyotis diffusa. J Chin Pharmaceut Sci. 11:pp.
54–58. 2002, http://118.145.16.238/Jwk_zgyxen/EN/abstract/abstract509.shtml.
|
|
12
|
Gupta S, Zhang D, Yi J and Shao J:
Anticancer activities of Oldenlandia diffusa. J Herb Pharmacother.
4:21–33. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Italiano JE Jr, Richardson JL, Patel-Hett
S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J and
Klement GL: Angiogenesis is regulated by a novel mechanism: Pro-
and anti-angiogenic proteins are organized into separate platelet
alpha granules and differentially released. Blood. 111:1227–1233.
2008. View Article : Google Scholar
|
|
14
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shiojima I and Walsh K: Role of Akt
signaling in vascular homeostasis and angiogenesis. Circ Res.
90:1243–1250. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kandel ES and Hay N: The regulation and
activities of the multi-functional serine/threonine kinase Akt/PKB.
Exp Cell Res. 253:210–229. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mazure NM, Chen EY, Laderoute KR and
Giaccia AJ: Induction of vascular endothelial growth factor by
hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt
signaling pathway in Ha-ras-transformed cells through a hypoxia
inducible factor-1 transcriptional element. Blood. 90:3322–3331.
1997.PubMed/NCBI
|
|
18
|
Arsham AM, Plas DR, Thompson CB and Simon
MC: Akt and hypoxia-inducible factor-1 independently enhance tumor
growth and angiogenesis. Cancer Res. 64:3500–3507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun JF, Phung T, Shiojima I, Felske T,
Upalakalin JN, Feng D, Kornaga T, Dor T, Dvorak AM, Walsh K, et al:
Microvascular patterning is controlled by fine-tuning the Akt
signal. Proc Natl Acad Sci USA. 102:128–133. 2005. View Article : Google Scholar :
|
|
20
|
Shiojima I, Sato K, Izumiya Y, Schiekofer
S, Ito M, Liao R, Colucci WS and Walsh K: Disruption of coordinated
cardiac hypertrophy and angiogenesis contributes to the transition
to heart failure. J Clin Invest. 115:2108–2118. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagoshi T, Matsui T, Aoyama T, Leri A,
Anversa P, Li L, Ogawa W, del Monte F, Gwathmey JK, Grazette L, et
al: PI3K rescues the detrimental effects of chronic Akt activation
in the heart during ischemia/reperfusion injury. J Clin Invest.
115:2128–2138. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Q, Oh CK, Messadi DV, Duong HS,
Kelly AP, Soo C, Wang L and Le AD: Hypoxia-induced HIF-1 alpha
accumulation is augmented in a co-culture of keloid fibroblasts and
human mast cells: Involvement of ERK1/2 and PI-3K/Akt. Exp Cell
Res. 312:145–155. 2006. View Article : Google Scholar
|
|
23
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al; SHARP Investigators Study Group. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wilhelm S, Carter C, Lynch M, Lowinger T,
Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery
and development of sorafenib: A multikinase inhibitor for treating
cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge
Y, Newman RA, Cohen L, Liu L, Thornton B, et al: Pilot study of
huachansu in patients with hepatocellular carcinoma, non-small-cell
lung cancer, or pancreatic cancer. Cancer. 115:5309–5318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee DY, Yasuda M, Yamamoto T, Yoshida T
and Kuroiwa Y: Bufalin inhibits endothelial cell proliferation and
angiogenesis in vitro. Life Sci. 60:127–134. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao Y, Li HX, Xu LT, Wang P, Xu LY, Cohen
L, Yang PY, Gu K and Meng ZQ: Bufalin enhances the
anti-proliferative effect of sorafenib on human hepatocellular
carcinoma cells through downregulation of ERK. Mol Biol Rep.
39:1683–1689. 2012. View Article : Google Scholar
|
|
28
|
Wedge SR, Ogilvie DJ, Dukes M, Kendrew J,
Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove
HL, et al: ZD6474 inhibits vascular endothelial growth factor
signaling, angiogenesis, and tumor growth following oral
administration. Cancer Res. 62:4645–4655. 2002.PubMed/NCBI
|
|
29
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
30
|
Auerbach R, Lewis R, Shinners B, Kubai L
and Akhtar N: Angiogenesis assays: A critical overview. Clin Chem.
49:32–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koch S, Tugues S, Li X, Gualandi L and
Claesson-Welsh L: Signal transduction by vascular endothelial
growth factor receptors. Biochem J. 437:169–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ferrara N: VEGF as a therapeutic target in
cancer. Oncology. 69(Suppl 3): 11–16. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Skinner HD, Zheng JZ, Fang J, Agani F and
Jiang BH: Vascular endothelial growth factor transcriptional
activation is mediated by hypoxia-inducible factor 1alpha, HDM2,
and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT
signaling. J Biol Chem. 279:45643–45651. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Graupera M, Guillermet-Guibert J, Foukas
LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J,
Cutillas PR, et al: Angiogenesis selectively requires the p110alpha
isoform of PI3K to control endothelial cell migration. Nature.
453:662–666. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Staal SP: Molecular cloning of the akt
oncogene and its human homologues AKT1 and AKT2: Amplification of
AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci
USA. 84:5034–5037. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tanaka H, Fujita N and Tsuruo T:
3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB
kinase beta (IkkB) phosphorylation activates NF-kappaB signaling. J
Biol Chem. 280:40965–40973. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gómez-Raposo C, Mendiola M, Barriuso J,
Casado E, Hardisson D and Redondo A: Angiogenesis and ovarian
cancer. Clin Transl Oncol. 11:564–571. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ellis L, Hammers H and Pili R: Targeting
tumor angiogenesis with histone deacetylase inhibitors. Cancer
Lett. 280:145–153. 2009. View Article : Google Scholar
|
|
41
|
Li Q, Michaud M, Canosa S, Kuo A and Madri
JA: GSK-3β: A signaling pathway node modulating neural stem cell
and endothelial cell interactions. Angiogenesis. 14:173–185. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zeng Z, Huang WD, Gao Q, Su ML, Yang YF,
Liu ZC and Zhu BH: Arnebin-1 promotes angiogenesis by inducing
eNOS, VEGF and HIF-1α expression through the PI3K-dependent
pathway. Int J Mol Med. 36:685–697. 2015.PubMed/NCBI
|
|
43
|
Marimpietri D, Nico B, Vacca A, Mangieri
D, Catarsi P, Ponzoni M and Ribatti D: Synergistic inhibition of
human neuroblastoma-related angiogenesis by vinblastine and
rapamycin. Oncogene. 24:6785–6795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nakamura K, Martin KC, Jackson JK, Beppu
K, Woo CW and Thiele CJ: Brain-derived neurotrophic factor
activation of TrkB induces vascular endothelial growth factor
expression via hypoxia-inducible factor-1alpha in neuroblastoma
cells. Cancer Res. 66:4249–4255. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter
T and Vogt PK: Phosphatidylinositol 3-kinase signaling controls
levels of hypoxia-inducible factor 1. Cell Growth Differ.
12:363–369. 2001.PubMed/NCBI
|
|
46
|
Bajaj A, Zheng Q, Adam A, Vincent P and
Pumiglia K: Activation of endothelial ras signaling bypasses
senescence and causes abnormal vascular morphogenesis. Cancer Res.
70:3803–3812. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah
G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I,
Nagy JA, et al: Pathological angiogenesis is induced by sustained
Akt signaling and inhibited by rapamycin. Cancer Cell. 10:159–170.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Takahashi T, Yamaguchi S, Chida K and
Shibuya M: A single autophosphorylation site on KDR/Flk-1 is
essential for VEGF-A-dependent activation of PLC-gamma and DNA
synthesis in vascular endothelial cells. EMBO J. 20:2768–2778.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar
|
